SCHEMBL10175642

SCHEMBL10175642

Cc1cnc2c(c1)OCCCO2

nearest known ligand 0.33

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.33
RAB9A P51151 3/20 0.33
CYP1A2 P05177 2/20 0.33
ALDH1A1 P00352 2/20 0.33
CHEK1 O14757 1/20 0.33
CCR1 P32246 1/20 0.32
CCR5 P51681 1/20 0.32
CCR8 P51685 1/20 0.32
NOS3 P29474 1/20 0.32
NOS1 P29475 1/20 0.32
NOS2 P35228 1/20 0.32
FFAR4 Q5NUL3 1/20 0.32
USP9X Q93008 2/20 0.32
PIK3CA P42336 1/20 0.31
CYP2C19 P33261 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
GAA P10253 1/20 0.30
MAPT P10636 1/20 0.30
HSD17B10 Q99714 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11999826 0.92 RAB9A (0.37) NPC1RAB9ACYP1A2ALDH1A1CCR1
SCHEMBL25876887 0.87 LMNA (0.38) NPC1RAB9ACYP1A2CCR1CCR5
SCHEMBL13459875 0.80 RAB9A (0.36) NPC1RAB9ACYP1A2ALDH1A1CCR1
SCHEMBL21024285 0.77 KDM4E (0.35) CHEK1PIK3CAGAAMAPT
SCHEMBL21461907 0.77 HTT (0.36) NPC1RAB9ACHEK1PIK3CASMN1; SMN2
SCHEMBL13459876 0.76 NPC1 (0.32) NPC1RAB9ACCR1CCR5CCR8
SCHEMBL11926935 0.76 ACHE (0.35) CYP1A2CCR1CCR5CCR8NOS3
SCHEMBL21201805 0.72 GRM5 (0.44) ALDH1A1CHEK1GAAMAPTHSD17B10
SCHEMBL27415956 0.72 PDGFRB (0.42) NPC1RAB9AALDH1A1CHEK1SMN1; SMN2
SCHEMBL13174578 0.71 CYP1A2 (0.34) CYP1A2ALDH1A1CCR1CCR5CCR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8969342-B2 Compounds and methods for treating mammalian gastrointestinal microbial infections BRANDEIS UNIVERSITY (US) 2015-03-03 US disclosed
US-20120101096-A1 Compounds and Methods for Treating Mammalian Gastrointestinal Microbial Infections University of Georgia Foundation, Inc. (US) 2012-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120101096-A1 Compounds and Methods for Treating Mammalian Gastrointestinal Microbial Infections IMPDH1, IMPDH2, IMPA1 NPC1 641/4885RAB9A 1748/4885CYP1A2 183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.